<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03406169</url>
  </required_header>
  <id_info>
    <org_study_id>C.2017.001</org_study_id>
    <nct_id>NCT03406169</nct_id>
  </id_info>
  <brief_title>Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy</brief_title>
  <official_title>Patterns of Erectile Recovery After Robotic-Assisted Laparoscopic Prostatectomy With and Without Penile Rehabilitation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brooke Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Walter Reed National Military Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Brooke Army Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a prospective, randomized, double-blind, placebo-controlled drug study to&#xD;
      evaluate the pattern of erectile function recovery after robotic assisted laparoscopic&#xD;
      prostatectomy (RALP). We hope to illustrate that early and continuous therapy with either&#xD;
      Sildenafil citrate or pentoxyfylline after nerve sparing RALP will promote improved erectile&#xD;
      function.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluation of erectile function with the International Index of Erectile Function&#xD;
      Questionnaire (IIEF) and measurement of penile length any time between the prostate biopsy&#xD;
      and 3 days prior to RALP will be performed.&#xD;
&#xD;
      Patients will undergo a unilateral or bilateral nerve sparing-RALP.&#xD;
&#xD;
      Patients will be randomized to receive either 25mg Viagra twice daily, 400mg pentoxifylline&#xD;
      twice daily or placebo twice daily, starting on the first postoperative day after surgery and&#xD;
      continuing for one year. The biostatistician generates a table of random numbers. 120&#xD;
      subjects anticipated to enroll at Brooke Army Medical Center will be divided into 3 groups,&#xD;
      sildenafil, pentoxifylline or placebo. The randomization table will be given to the research&#xD;
      pharmacist.&#xD;
&#xD;
      Patients will have their erectile function evaluated at 3 months, 6 months, 9 months, and 12&#xD;
      months with IIEF and sexual intercourse diary. These visits are routine for post-operative&#xD;
      care following a RALP, however, completion of the IIEF and sexual intercourse diary are being&#xD;
      performed for study purposes.&#xD;
&#xD;
      Patients will stop therapy at 12 months and penile length will be re-measured. Measurement of&#xD;
      penile length will be done for study purposes at the standard 1 year post-operative follow up&#xD;
      visit.&#xD;
&#xD;
      Patient will undergo a 6 week washout period during which neither drug will be used, then&#xD;
      repeat analysis of erectile function with IIEF will be performed, after which they may&#xD;
      restart standard erectile dysfunction therapy as desired. This washout period and follow up&#xD;
      will be for study purposes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 13, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile function</measure>
    <time_frame>12 months post surgery</time_frame>
    <description>As measured by IIEF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Penile length</measure>
    <time_frame>12 months post surgery</time_frame>
    <description>Stretched length in cm from pubis to coronal ridge</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Erectile Dysfunction</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Sildenafil 25mg Oral Tablet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25mg sildenafil citrate twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400mg pentoxifylline twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sildenafil 25 MG Oral Tablet</intervention_name>
    <description>twice a day dosing</description>
    <arm_group_label>Sildenafil 25mg Oral Tablet</arm_group_label>
    <other_name>viagra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline</intervention_name>
    <description>400mg twice a day</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <other_name>trental</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo twice a day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients who have had a prostate biopsy positive for prostate cancer.&#xD;
&#xD;
          2. Patient must be age 30 - 89 years.&#xD;
&#xD;
          3. Patient must be willing to sign the Institutional Review Board approved consent.&#xD;
&#xD;
          4. Patient must have had (or be about to undergo) bilateral or unilateral nerve sparing&#xD;
             RALP.&#xD;
&#xD;
          5. Patient must have an International IIEF equal to or greater than 21.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with known unstable angina, uncontrolled hypertension, congestive heart&#xD;
             failure, or cardiovascular accident within the preceding 2 weeks.&#xD;
&#xD;
          2. Patients being treated with nitrate therapy.&#xD;
&#xD;
          3. Patients with significant renal or hepatic impairment, cerebrovascular disease.&#xD;
&#xD;
          4. Patients with prior erectile dysfunction as indicated by the initial IIEF.&#xD;
&#xD;
          5. Patients younger than 30 years of age.&#xD;
&#xD;
          6. Patients who did/will not have a unilateral or bilateral nerve sparing radical&#xD;
             prostatectomy.&#xD;
&#xD;
          7. Patients who have had a prior reaction to Sildenafil or pentoxifylline.&#xD;
&#xD;
          8. Patients taking any potent inhibitor of cytochrome P450 3A4 (e.g., ketoconazole,&#xD;
             itraconazole, erythromycin, etc.).&#xD;
&#xD;
          9. Patients with a clinically significant abnormality on preoperative ECG that in the&#xD;
             opinion of the investigator may increase the patient's cardiovascular risk in this&#xD;
             study.&#xD;
&#xD;
         10. Patients with a history of left ventricular outflow obstruction (e.g. aortic stenosis,&#xD;
             idiopathic hypertrophic subaortic stenosis).&#xD;
&#xD;
         11. Patients with resting hypotension (BP &lt; 90/50 mm Hg), or resting hypertension (BP &gt;&#xD;
             170/110 mm Hg).&#xD;
&#xD;
         12. Patients with retinitis pigmentosa.&#xD;
&#xD;
         13. Patients with a bleeding disorder.&#xD;
&#xD;
         14. Patients with active peptic ulceration.&#xD;
&#xD;
         15. Patients with conditions that may predispose to priapism (e.g. sickle cell anemia,&#xD;
             multiple myeloma, or leukemia).&#xD;
&#xD;
         16. Patients who have previously experienced non-arteritic ischemic optic neuropathy&#xD;
             (NAION).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Must have a prostate</gender_description>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuwong B Mwamukonda, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brooke Army Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Schadee, RN</last_name>
    <phone>210 916-1640</phone>
    <email>janet.s.schadee.civ@mail.mil</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pansy Uberoi, MD</last_name>
    <phone>210 916-1163</phone>
    <email>pansy.uberoi.mil@mail.mil</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Brooke Army Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ileana King-Letzkus</last_name>
      <phone>210-916-2000</phone>
      <email>ileana.e.king-letzkus.civ@mail.mil</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2018</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brooke Army Medical Center</investigator_affiliation>
    <investigator_full_name>Kuwong B Mwamukonda</investigator_full_name>
    <investigator_title>Staff Urologist</investigator_title>
  </responsible_party>
  <keyword>penile rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

